Kenai Therapeutics
Pioneering next generation approaches to cure neurological conditions.
United States · $90.0M raised
- Website
- kenaitx.com
- Total Funding
- $90.0M
- Last Round
- $82.0M Series AJan 2026
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
About
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine-neuron replacement cell therapies and gene-modified medicines for neurological conditions. Its programs aim to provide disease-modifying or potentially curative treatments that go beyond symptom management for neurodegenerative disease. The company focuses on restoring function and quality of life through next-generation approaches to neuron replacement and neurological-cell therapy.
Summary
Kenai Therapeutics is a Biotech company based in United States. It has raised $90.0M in total across 2 rounds, most recently a $82.0M Series A round in Jan 2026. Investors include Alaska Permanent Fund, Cure Ventures and The Column Group.
Funding History
Jan 2026
Sign up to see all 2 events
Funding: Grant. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/kenai-therapeutics"><img src="https://indexed.vc/api/badge/company/kenai-therapeutics" alt="Kenai Therapeutics on Indexed.vc" width="260" height="76" /></a>